VALEANT PRICE TARGET INCREASED TO $195, 117% UPSIDE
Valeant Pharmaceuticals Inc (NYSE:VRX)‘s stock had its “buy” rating reiterated by investment analysts at Guggenheim in a research note issued on Thursday, ARN reports. They presently have a $195.00 target price on the specialty pharmaceutical company’s stock. Guggenheim’s price objective points to a potential upside of 117.22% from the company’s current price.
Several other research firms have also commented on VRX.
TD Securities reiterated a “buy” rating and issued a $300.00 price target on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, September 23rd.
Zacks Investment Research lowered shares of Valeant Pharmaceuticals Intl from a “buy” rating to a “hold” rating in a research report on Wednesday, September 23rd.
RBC Capital reiterated an “outperform” rating and issued a $279.00 price target on shares of Valeant Pharmaceuticals Intl in a research report on Monday, September 28th.
Morgan Stanley lowered shares of Valeant Pharmaceuticals Intl from an “overweight” rating to an “equal weight” rating in a research report on Monday, October 5th.
Scotiabank increased their price target on shares of Valeant Pharmaceuticals Intl from $235.00 to $295.00 in a research report on Thursday, October 1st.
Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company.
The stock has a consensus rating of “Buy” and an average price target of $156.47.
Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) traded up 4.95% during mid-day trading on Thursday, reaching $89.77. The company’s stock had a trading volume of 5,001,912 shares. Valeant Pharmaceuticals Intl has a 1-year low of $69.33 and a 1-year high of $263.81. The firm’s 50 day moving average price is $99.42 and its 200-day moving average price is $168.98. The company has a market capitalization of $30.80 billion and a price-to-earnings ratio of 51.56.
Valeant Pharmaceuticals Intl (NYSE:VRX) last issued its earnings results on Monday, October 19th. The specialty pharmaceutical company reported $2.74 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.06. The company had revenue of $2.79 billion for the quarter, compared to analyst estimates of $2.06 billion. The company’s quarterly revenue was up 35.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.58 earnings per share. On average, analysts predict that Valeant Pharmaceuticals Intl will post $10.35 EPS for the current year.
Several hedge funds recently added to or reduced their stakes in VRX.
Kistler-Tiffany Companies increased its stake in Valeant Pharmaceuticals Intl by 25.3% in the fourth quarter. Kistler-Tiffany Companies now owns 1,115 shares of the specialty pharmaceutical company’s stock worth $113,000 after buying an additional 225 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft increased its stake in Valeant Pharmaceuticals Intl by 6.6% in the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft now owns 73,800 shares of the specialty pharmaceutical company’s stock worth $12,732,000 after buying an additional 4,600 shares during the period. Gillespie Robinson & Grimm increased its stake in Valeant Pharmaceuticals Intl by 12.3% in the fourth quarter. Gillespie Robinson & Grimm now owns 123,815 shares of the specialty pharmaceutical company’s stock worth $12,586,000 after buying an additional 13,525 shares during the period. Jennison Associates increased its stake in Valeant Pharmaceuticals Intl by 0.8% in the third quarter. Jennison Associates now owns 308,200 shares of the specialty pharmaceutical company’s stock worth $54,977,000 after buying an additional 2,364 shares during the period. Finally, Janus Capital Management increased its stake in Valeant Pharmaceuticals Intl by 36.1% in the third quarter. Janus Capital Management now owns 3,258,686 shares of the specialty pharmaceutical company’s stock worth $581,295,000 after buying an additional 863,566 shares during the period.
In other news, Director Ronald Harold Farmer acquired 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 21st. The shares were purchased at an average cost of $181.60 per share, for a total transaction of $272,400.00. Following the transaction, the director now directly owns 15,532 shares in the company, valued at approximately $2,820,611.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (NYSE:VRX) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.
Read more at http://www.stockhouse.com/companies/bullboard...d1iFER6.99
Valeant Pharmaceuticals Inc (NYSE:VRX)‘s stock had its “buy” rating reiterated by investment analysts at Guggenheim in a research note issued on Thursday, ARN reports. They presently have a $195.00 target price on the specialty pharmaceutical company’s stock. Guggenheim’s price objective points to a potential upside of 117.22% from the company’s current price.
Several other research firms have also commented on VRX.
TD Securities reiterated a “buy” rating and issued a $300.00 price target on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, September 23rd.
Zacks Investment Research lowered shares of Valeant Pharmaceuticals Intl from a “buy” rating to a “hold” rating in a research report on Wednesday, September 23rd.
RBC Capital reiterated an “outperform” rating and issued a $279.00 price target on shares of Valeant Pharmaceuticals Intl in a research report on Monday, September 28th.
Morgan Stanley lowered shares of Valeant Pharmaceuticals Intl from an “overweight” rating to an “equal weight” rating in a research report on Monday, October 5th.
Scotiabank increased their price target on shares of Valeant Pharmaceuticals Intl from $235.00 to $295.00 in a research report on Thursday, October 1st.
Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company.
The stock has a consensus rating of “Buy” and an average price target of $156.47.
Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) traded up 4.95% during mid-day trading on Thursday, reaching $89.77. The company’s stock had a trading volume of 5,001,912 shares. Valeant Pharmaceuticals Intl has a 1-year low of $69.33 and a 1-year high of $263.81. The firm’s 50 day moving average price is $99.42 and its 200-day moving average price is $168.98. The company has a market capitalization of $30.80 billion and a price-to-earnings ratio of 51.56.
Valeant Pharmaceuticals Intl (NYSE:VRX) last issued its earnings results on Monday, October 19th. The specialty pharmaceutical company reported $2.74 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.06. The company had revenue of $2.79 billion for the quarter, compared to analyst estimates of $2.06 billion. The company’s quarterly revenue was up 35.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.58 earnings per share. On average, analysts predict that Valeant Pharmaceuticals Intl will post $10.35 EPS for the current year.
Several hedge funds recently added to or reduced their stakes in VRX.
Kistler-Tiffany Companies increased its stake in Valeant Pharmaceuticals Intl by 25.3% in the fourth quarter. Kistler-Tiffany Companies now owns 1,115 shares of the specialty pharmaceutical company’s stock worth $113,000 after buying an additional 225 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft increased its stake in Valeant Pharmaceuticals Intl by 6.6% in the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft now owns 73,800 shares of the specialty pharmaceutical company’s stock worth $12,732,000 after buying an additional 4,600 shares during the period. Gillespie Robinson & Grimm increased its stake in Valeant Pharmaceuticals Intl by 12.3% in the fourth quarter. Gillespie Robinson & Grimm now owns 123,815 shares of the specialty pharmaceutical company’s stock worth $12,586,000 after buying an additional 13,525 shares during the period. Jennison Associates increased its stake in Valeant Pharmaceuticals Intl by 0.8% in the third quarter. Jennison Associates now owns 308,200 shares of the specialty pharmaceutical company’s stock worth $54,977,000 after buying an additional 2,364 shares during the period. Finally, Janus Capital Management increased its stake in Valeant Pharmaceuticals Intl by 36.1% in the third quarter. Janus Capital Management now owns 3,258,686 shares of the specialty pharmaceutical company’s stock worth $581,295,000 after buying an additional 863,566 shares during the period.
In other news, Director Ronald Harold Farmer acquired 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 21st. The shares were purchased at an average cost of $181.60 per share, for a total transaction of $272,400.00. Following the transaction, the director now directly owns 15,532 shares in the company, valued at approximately $2,820,611.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (NYSE:VRX) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.
Read more at http://www.stockhouse.com/companies/bullboard...d1iFER6.99
